Stryker has received 510(k) clearance from the FDA for its Incompass Total Ankle System, a next-generation implant targeting ...

Johnson & Johnson JNJ is one of the few large drug and medical device companies with a presence in both the pharmaceuticals ...

Suryakumar Yadav surprised fans with a health update on Wednesday, June 25. From a Munich hospital bed, SYK shared an ...

Stryker just received FDA clearance for its Incompass® Total Ankle System, reinforcing its drive for surgical innovation and ...

Stryker stock is trading -6.87% below its average target price of $421.46 after marking a 1.6% during today's afternoon ...

This was the stock's fourth consecutive day of gains.

Stryker has secured FDA clearance for its Incompass total ankle system to treat patients whose ankle joints have been damaged by severe rheumatoid, post-traumatic or degenerative arthritis. The ...

Stryker (NYSE:SYK) recently received FDA clearance for its Incompass® Total Ankle System, a significant product innovation that highlights the company's commitment to advancing patient care. Over the ...

According to Benzinga Pro, Stryker's peer group average for short interest as a percentage of float is 5.30%, which means the ...

Stryker (NYSE:SYK) announced today that it received FDA 510(k) clearance for its Incompass total ankle system.

Overall, the average yield on cost of my new investments in April averaged around 7.4%, reinforcing my belief in BDCs as a ...

Gross margins declined to 66.4% in the first quarter from 67.6% a year ago due to increased depreciation, a higher mix of ...